# US stocks drop as FDA rejects lung cancer drug approval

> Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.
- Title: US stocks drop as FDA rejects lung cancer drug approval
- Summary: Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.
- Keywords: us stocks, summit therapeutics, fda, ivonescimab, lung cancer drug, chemotherapy, fda approval, The Economic Times
- URL: https://shortify.news/The_Economic_Times/us-stocks-drop-as-fda-rejects-lung-cancer-drug-approval
- Source: The Economic Times — https://economictimes.indiatimes.com/markets/us-stocks/news/us-stocks-summit-shares-drop-after-us-fda-declines-to-approve-lung-cancer-drug/articleshow/135894815.cms
- Author: Reuters
- Published: 2026-11-16T15:48:00+00:00
- Read time: 1 min
- Topics: us stocks, summit therapeutics, fda, ivonescimab, lung cancer drug, chemotherapy, fda approval, money, business
## FDA rejects lung cancer drug
US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab.
## Shares drop 14%
Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.
## Drug study results
Late-stage study showed no statistically significant overall survival benefit for ivonescimab.
## Regional patient outcomes
Follow-up data showed greater survival benefit in Chinese patients than North American and European patients.
## FDA's regulatory impact
FDA decision sets meaningful regulatory precedent for lung cancer drug class with implications for Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
## Drug mechanism
Ivonescimab targets proteins PD-1 and VEGF to help tumors evade immune system and spread.
## Investor reaction
Investors await first-line trial data comparing ivonescimab against Merck's Keytruda for lung cancer treatment.
## Key takeaway

US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%.

---

Summary: Shortify — https://shortify.news/The_Economic_Times/us-stocks-drop-as-fda-rejects-lung-cancer-drug-approval
Reporting: The Economic Times — https://economictimes.indiatimes.com/markets/us-stocks/news/us-stocks-summit-shares-drop-after-us-fda-declines-to-approve-lung-cancer-drug/articleshow/135894815.cms

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.